Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + docetaxel versus doxorubicin for first-line advanced soft tissue sarcoma
ISRCTN07742377Phase 3Completed
- Sponsor
- University College London
- Start
- Jan 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, docetaxel and doxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by University College London. Primary endpoint: Progression-free survival. Started Jan 2010; status: completed.
02
Drugs
gemcitabinedocetaxeldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ISRCTN07742377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN07742377.